Elisa Grossmann, Hannah-Lou Schilling, Christina Magnussen
{"title":"The Prevention of Heart Failure Risk Assessment and Early Intervention along the Cardiovascular Continuum.","authors":"Elisa Grossmann, Hannah-Lou Schilling, Christina Magnussen","doi":"10.1007/s11897-026-00751-2","DOIUrl":null,"url":null,"abstract":"<p><p>PURPOSE OF REVIEW: Heart failure (HF) is a complex clinical syndrome that develops as the final common manifestation of diverse cardiovascular disorders along a variety of different pathophysiological pathways. The trajectory towards HF is set decades earlier by a combination of non-modifiable risk factors and a substantial number of principally modifiable risk factors. Conceptualizing HF prevention as a continuum — from primordial prevention to tertiary prevention — highlights how consistently these factors determine and drive the risk to develop HF. Early at-risk and pre-HF stages therefore represent the most appropriate window for effective prevention, yet they are still underrated and under-recognized in clinical practice. RECENT FINDINGS: A broad array of modifiable risk factors, together with echocardiographic and laboratory markers, are involved in disease progression. Combining these domains may optimize risk stratification and enable more targeted prevention efforts. The rapidly evolving heart failure pandemic, largely driven by the rising prevalence of conditions that are to a substantial extent attributable to modifiable risk factors, poses an enormous burden on health systems worldwide. In consequence, enhanced global awareness, comprehensive assessment and more effective control of modifiable risk factors are urgently needed to prevent HF. A multidimensional risk assessment approach could facilitate early identification and timely intervention to prevent progression to symptomatic HF. </p>","PeriodicalId":10830,"journal":{"name":"Current Heart Failure Reports","volume":"23 1","pages":""},"PeriodicalIF":3.7000,"publicationDate":"2026-03-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13002667/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Heart Failure Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s11897-026-00751-2","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
PURPOSE OF REVIEW: Heart failure (HF) is a complex clinical syndrome that develops as the final common manifestation of diverse cardiovascular disorders along a variety of different pathophysiological pathways. The trajectory towards HF is set decades earlier by a combination of non-modifiable risk factors and a substantial number of principally modifiable risk factors. Conceptualizing HF prevention as a continuum — from primordial prevention to tertiary prevention — highlights how consistently these factors determine and drive the risk to develop HF. Early at-risk and pre-HF stages therefore represent the most appropriate window for effective prevention, yet they are still underrated and under-recognized in clinical practice. RECENT FINDINGS: A broad array of modifiable risk factors, together with echocardiographic and laboratory markers, are involved in disease progression. Combining these domains may optimize risk stratification and enable more targeted prevention efforts. The rapidly evolving heart failure pandemic, largely driven by the rising prevalence of conditions that are to a substantial extent attributable to modifiable risk factors, poses an enormous burden on health systems worldwide. In consequence, enhanced global awareness, comprehensive assessment and more effective control of modifiable risk factors are urgently needed to prevent HF. A multidimensional risk assessment approach could facilitate early identification and timely intervention to prevent progression to symptomatic HF.
期刊介绍:
This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of heart failure. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as investigative, pharmacologic, and nonpharmacologic therapies, pathophysiology, and prevention. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.